Heron Therapeutics | HRTX - Sales Revenues


Heron Therapeutics reported $40.59M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
ALKERMES USD 392.91M 8.41M Mar/2026
Alnylam Pharmaceuticals USD 1.17B 70M Mar/2026
Amarin USD 49.22M 451K Dec/2025
ANI Pharmaceuticals USD 237.5M 9.56M Mar/2026
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 73.74M 190.29M Mar/2026
Eisai JPY 205.43B 14.51B Mar/2026
Emergent BioSolutions USD 276.6M 6.1M Dec/2023
GlaxoSmithKline GBP 7.63B 991M Mar/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Insmed USD 305.96M 42.16M Mar/2026
Ligand Pharmaceuticals USD 51.72M 7.94M Mar/2026
Merck USD 16.29B 110M Mar/2026
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Neurocrine Biosciences USD 811M 5.5M Mar/2026
Pacira USD 177M 19.87M Mar/2026
Regeneron Pharmaceuticals USD 3.6B 280M Mar/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sangamo BioSciences USD 356K 125K Jun/2024
Ultragenyx Pharmaceutical USD 136M 71M Mar/2026
Veracyte USD 139.07M 1.53M Mar/2026
Vertex Pharmaceuticals USD 2.99B 200M Mar/2026